Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer

被引：35

作者：

Cheng, Ying ^{[1
]}

Liu, Xiao-Qing ^{[2
]}

Fan, Yun ^{[3
]}

Liu, Yun-Peng ^{[4
]}

Liu, Yi ^{[5
]}

Liu, Ying ^{[1
]}

Ma, Li-Xia ^{[1
]}

Liu, Xian-Hong ^{[1
]}

Li, Hui ^{[1
]}

Bao, Hui-Zheng ^{[1
]}

Liu, Jing-Jing ^{[1
]}

Zhang, Shuang ^{[1
]}

Wu, Chun-Jiao ^{[1
]}

机构：

[1] Jilin Prov Canc Hosp, Dept Med Oncol, Changchun, Peoples R China

[2] Acad Mil Med Sci, Affiliated Hosp, Dept Pulm Oncol, Beijing, Peoples R China

[3] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China

[4] China Med Univ, Dept Med Oncol, Hosp 1, Shenyang 110001, Peoples R China

[5] Acad Mil Med Sci, Affiliated Hosp, Lab Oncol, Translat Med Ctr, Beijing, Peoples R China

来源：

FUTURE ONCOLOGY | 2016年 / 12卷 / 06期

关键词：

circulating tumor cells; prognosis; small-cell lung cancer; CLINICAL-SIGNIFICANCE; PROSTATE-CANCER; SURVIVAL; PROGRESSION; TRIAL; BLOOD;

D O I：

10.2217/fon.15.346

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aims: As data on the use of circulating tumor cells (CTCs) to predict patient outcomes in extensive-stage small-cell lung cancer (ES-SCLC) remain inconclusive, we investigated the clinical value of CTC determination in an open-label, multicenter study of 91 patients with newly diagnosed ES-SCLC. Materials & methods: Blood CTC counts were determined using the CellSearch (R) system at baseline, after the second cycle of chemotherapy, and on disease progression. Results & conclusion: Following the second cycle of treatment, CTC numbers and the change in CTCs were strong, significant and independent indicators for both progression-free survival and overall survival in ES-SCLC. The CTC change was associated with both refractory disease (response to initial therapy <= 3 months) and sensitive disease (response to initial therapy >3 months).

引用

页码：789 / 799

页数：11

共 25 条

[1] OPINION Challenges in circulating tumour cell research [J].

Alix-Panabieres, Catherine ;

Pantel, Klaus .

NATURE REVIEWS CANCER, 2014, 14 (09) :623-631

[2] Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases [J].

Allard, WJ ;

Matera, J ;

Miller, MC ;

Repollet, M ;

Connelly, MC ;

Rao, C ;

Tibbe, AGJ ;

Uhr, JW ;

Terstappen, LWMM .

CLINICAL CANCER RESEARCH, 2004, 10 (20) :6897-6904

[3] Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer [J].

Budd, G. Thomas ;

Cristofanilli, Massimo ;

Ellis, Mathew J. ;

Stopeck, Allison ;

Borden, Ernest ;

Miller, M. Craig ;

Matera, Jeri ;

Repollet, Madeline ;

Doyle, Gerald V. ;

Terstappen, Leon W. M. M. ;

Hayes, Daniel F. .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6403-6409

[4] Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer [J].

Cohen, Steven J. ;

Punt, Cornelis J. A. ;

Iannotti, Nicholas ;

Saidman, Bruce H. ;

Sabbath, Kert D. ;

Gabrail, Nashat Y. ;

Picus, Joel ;

Morse, Michael ;

Mitchell, Edith ;

Miller, M. Craig ;

Doyle, Gerald V. ;

Tissing, Henk ;

Terstappen, Leon W. M. M. ;

Meropol, Neal J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (19) :3213-3221

[5] Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer [J].

Cristofanilli, M ;

Hayes, DF ;

Budd, GT ;

Ellis, MJ ;

Stopeck, A ;

Reuben, JM ;

Doyle, GV ;

Matera, J ;

Allard, WJ ;

Miller, MC ;

Fritsche, HA ;

Hortobagyi, GN ;

Terstappen, LWMM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1420-1430

[6] Circulating tumor cells, disease progression, and survival in metastatic breast cancer [J].

Cristofanilli, M ;

Budd, GT ;

Ellis, MJ ;

Stopeck, A ;

Matera, J ;

Miller, MC ;

Reuben, JM ;

Doyle, GV ;

Allard, WJ ;

Terstappen, LWMM ;

Hayes, DF .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (08) :781-791

[7] Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer [J].

Danila, Daniel C. ;

Heller, Glenn ;

Gignac, Gretchen A. ;

Gonzalez-Espinoza, Rita ;

Anand, Aseem ;

Tanaka, Erika ;

Lilja, Hans ;

Schwartz, Lawrence ;

Larson, Steven ;

Fleisher, Martin ;

Scher, Howard I. .

CLINICAL CANCER RESEARCH, 2007, 13 (23) :7053-7058

[8] Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer [J].

de Bono, Johann S. ;

Scher, Howard I. ;

Montgomery, R. Bruce ;

Parker, Christopher ;

Miller, M. Craig ;

Tissing, Henk ;

Doyle, Gerald V. ;

Terstappen, Leon W. W. M. ;

Pienta, Kenneth J. ;

Raghavan, Derek .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6302-6309

[9] Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer [J].

Goldkorn, Amir ;

Ely, Benjamin ;

Quinn, David I. ;

Tangen, Catherine M. ;

Fink, Louis M. ;

Xu, Tong ;

Twardowski, Przemyslaw ;

Van Veldhuizen, Peter J. ;

Agarwal, Neeraj ;

Carducci, Michael A. ;

Monk, J. Paul, III ;

Datar, Ram H. ;

Garzotto, Mark ;

Mack, Philip C. ;

Lara, Primo, Jr. ;

Higano, Celestia S. ;

Hussain, Maha ;

Thompson, Ian Murchie, Jr. ;

Cote, Richard J. ;

Vogelzang, Nicholas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (11) :1136-+

[10] Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA [J].

Haber, Daniel A. ;

Velculescu, Victor E. .

CANCER DISCOVERY, 2014, 4 (06) :650-661

← 1 2 3 →